Perforin deficiency attenuates inflammation and tumor growth in colitis-associated cancer

Inflammatory Bowel Diseases

Volumn 16, Issue 4, 2010, Pages 559-567

  Waldner, Maximilian J ^a,b   Wirtz, Stefan ^a   Becker, Christoph ^a   Seidel, Daniel ^a   Tubbe, Ingrid ^a   Cappel, Kyra ^a   Hähnel, Patricia S ^c   Galle, Peter R ^a   Schuler, Martin ^c   Neurath, Markus F ^a,b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Colonic neoplasms; Inflammation; Inflammatory bowel disease; Perforin; T lymphocytes

Indexed keywords

AZOXYMETHANE; CASPASE 3; DEXTRAN SULFATE; EOMESODERMIN; FAS LIGAND; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; KI 67 ANTIGEN; PERFORIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATTENUATION; CANCER GROWTH; CANCER INFILTRATION; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLITIS; COLON CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; EPITHELIUM CELL; IMMUNE RESPONSE; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MOUSE; MUCOSA INFLAMMATION; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; WILD TYPE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; COLITIS; COLONIC NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; INTESTINAL MUCOSA; KILLER CELLS, NATURAL; MICE; MICE, INBRED C57BL; PORE FORMING CYTOTOXIC PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTES;

EID: 77949502494     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21107     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: Cancer J Clin. 2008;58:71-96.
2. Clevers H. At the crossroads of inflammation and cancer. Cell. 2004;118:671-674.
3. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581-592.
4. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-535.
5. Sachar DB. Cancer in Crohn's disease: dispelling the myths. Gut. 1994;35:1507-1508.
6. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476-487.
7. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity. 2004;21:137-148.
8. Waldner M, Schimanski CC, Neurath MF. Colon cancer and the immune system: The role of tumor invading T cells. World J Gastroenterol. 2006;12:7233-7238.
9. Kägi D, Ledermann B, Bürki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature. 1994;369:31-37.
10. Neufert C, Becker C, Neurath MF. An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc. 2007;2:1998-2004.
11. Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541-546.
12. Becker C, Fantini MC, Wirtz S, et al. In vivo imaging of colitis and colon cancer development in mice using high resolution chromoendoscopy. Gut. 2005;54:950-954.
13. Becker C, Wirtz S, Blessing M, et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest. 2003;112:693-706.
14. Mudter J, Amoussina L, Schenk M, et al. The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest. 2008;118:2415-2426.
15. van den Broek ME, Kägi D, Ossendorp F, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996;184:1781-1790.
16. Vermijlen D, Froelich CJ, Luo D, et al. Perforin and granzyme B induce apoptosis in FasL-resistant colon carcinoma cells. Cancer Immunol Immunother. 2001;50:212-217.
17. Perwez Hussain S, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer. 2007;121:2373-2380.
18. Becker C, Fantini MC, Schramm C, et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity. 2004;21:491-501.
19. Watt AG, House AK. Colonic carcinoma: a quantitative assessment of lymphocyte infiltration at the periphery of colonic tumors related to prognosis. Cancer. 1978;41:279-282.
20. House AK, Watt AG. Survival and the immune response in patients with carcinoma of the colorectum. Gut. 1979;20:868-874.
21. Pagès F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med. 2005;353:2654-2666.
22. Naito Y, Saito K, Shiiba K, et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998;58:3491-3494.
23. Atreya I, Schimanski CC, Becker C, et al. The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer. Gut. 2007;56:1572-1578.
24. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267-296.
25. Smith CL, Dulphy N, Salio M, et al. Immunotherapy of colorectal cancer. Br Med Bull. 2002;64:181-200.
26. Bergmann-Leitner ES, Duncan EH, Leitner WW. Identification and targeting of tumor escape mechanisms: a new hope for cancer therapy? Curr Pharm Des. 2003;9:2009-2023.
27. Andersen MH, Schrama D, Thor Straten P, et al. Cytotoxic T cells. J Invest Dermatol. 2006;126:32-41.
28. Filipovich AH. Hemophagocytic lymphohistiocytosis and related disorders. Curr Opinion Allergy Clin Immunol. 2006;6:410-415.
29. Henter JI. Biology and treatment of familial hemophagocytic lymphohistiocytosis: importance of perforin in lymphocyte-mediated cytotoxicity and triggering of apoptosis. Med Pediatr Oncol. 2002;38:305-309.
30. Grossman WJ, Verbsky JW, Barchet W, et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21:589-601.
31. Cao X, Cai SF, Fehniger TA, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007;27:635-646.
32. Müller S, Lory J, Corazza N, et al. Activated CD4+ and CD8+ cytotoxic cells are present in increased numbers in the intestinal mucosa from patients with active inflammatory bowel disease. Am J Pathol. 1998;152:261-268.
33. Melgar S, Hammarström S, Oberg A, et al. Cytolytic capabilities of lamina propria and intraepithelial lymphocytes in normal and chronically inflamed human intestine. Scand J Immunol. 2004;60:167-177.
34. Souza HS, Tortori CJ, Castelo-Branco MT, et al. Apoptosis in the intestinal mucosa of patients with inflammatory bowel disease: evidence of altered expression of FasL and perforin cytotoxic pathways. Int J Colorectal Dis. 2005;20:277-286.